USFDA13 Jul 2026, 06:50 pm
Alembic Pharma: USFDA Issues Warning Letter to Clinical Investigator
AI Summary
Alembic Pharmaceuticals Ltd has been informed that the USFDA has issued a Warning Letter dated July 10, 2026, to a Clinical Investigator associated with a bioequivalence study conducted at its Vadodara facility. The inspection occurred from March 3-7, 2025. The letter pertains to observations regarding the Informed Consent Form (ICF) and does not relate to data integrity. Alembic Pharma's preliminary assessment indicates no restriction on its facility's operations. The company is cooperating with the Clinical Investigator to submit a timely response. No material financial impact is identified at this stage.
Key Highlights
- USFDA issued a Warning Letter to a Clinical Investigator.
- Observations relate to Informed Consent Form, not data integrity.
- No operational restrictions on Alembic's facility expected.
- No material financial impact identified currently.
- Company is coordinating response with the investigator.
Price Impact
More from APLLTD